Evidence map›Paper›PMID 27686376›Full record

ArticleHaematologica2017

Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Sebastian Giebel, Myriam Labopin, Gerard Socié, Dietrich Beelen, Paul Browne, Liisa Volin, Slawomira Kyrcz-Krzemien, Ibrahim Yakoub-Agha, Mahmoud Aljurf, Depei Wu and 4 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Haematologica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 2 pooled it
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 2 syntheses or guidelines pooled it, 128 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 13 institutions in 8 countries.

Sebastian GiebelMaria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Poland sgiebel@io.gliwice.pl.
Myriam LabopinHospital St. Antoine, Paris, France.
Gerard SociéHospital St. Louis, Paris, France.
Dietrich BeelenUniversity Hospital, Essen, Germany.
Paul BrowneSt. James's Hospital - Trinity College, Dublin, Ireland.
Liisa VolinHelsinki University Central Hospital, Finland.
Slawomira Kyrcz-KrzemienSilesian Medical University, Katowice, Poland.
Ibrahim Yakoub-AghaUniversity Lille, Inserm, CHU Lille, U995 - LIRIC - Lille Inflammation Research, International Center, Lille, France.
Mahmoud AljurfKing Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
Depei WuFirst Affiliated Hospital of Soochow University, Suzhou, China.
Mauricette MichalletCentre Hospitalier Lyon Sud - Service Hematologie, Lyon, France.
Renate ArnoldCharité Universitätsmedizin Berlin - Campus Virchow Klinikum Berlin, Germany.
Mohamad MohtyHospital St. Antoine, Paris, France.
Arnon NaglerAcute Leukemia Working Party of the EBMT, France.
Acute Leukemia French Association · FRAssistance Publique – Hôpitaux de Paris · FRCentre Hospitalier Universitaire de Lille · FRCharité - Universitätsmedizin Berlin · DEEssen University Hospital · DEFirst Affiliated Hospital of Soochow University · CNHelsinki University Hospital · FIHôpital Saint-Louis · FRHospices Civils de Lyon · FRKing Faisal University · SAMedical University of Silesia · PLSheba Medical Center · ILTrinity College Dublin · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allogeneic hematopoietic cell transplantation is widely used to treat adults with high-risk acute lymphoblastic leukemia. The aim of this study was to analyze whether the results changed over time and to identify prognostic factors. Adult patients treated between 1993 and 2012 with myeloablative allogeneic hematopoietic cell transplantation from HLA matched sibling (n=2681) or unrelated (n=2178) donors in first complete remission were included. For transplantations from sibling donors performed between 2008 and 2012, 2-year probabilities of overall survival were: 76% (18-25 years old), 69% (26-35 and 36-45 years old) and 60% (46-55 years old). Among recipients of transplantations from unrelated donors, the respective survival rates were 66%, 70%, 61%, and 62%. In comparison with the 1993-2007 period, significant improvements were observed for all age groups except for the 26-35-year old patients. In a multivariate model, transplantations performed between 2008 and 2012, when compared to 1993-2007, were associated with significantly reduced risks of non-relapse mortality (Hazard Ratio 0.77, P=0.00006), relapse (Hazard Ratio 0.85, P=0.007), treatment failure (Hazard Ratio 0.81, P<0.00001), and overall mortality (Hazard Ratio 0.79, P<0.00001). In the analysis restricted to transplantations performed between 2008 and 2012, the use of total body irradiation-based conditioning was associated with reduced risk of relapse (Hazard Ratio 0.48, P=0.004) and treatment failure (Hazard Ratio 0.63, P=0.02). We conclude that results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia improved significantly over time. Total body irradiation should be considered as the preferable type of myeloablative conditioning.

Indexed as

Hematopoietic Stem Cell TransplantationRemission InductionAdolescentAdultFemaleHumansMaleMiddle AgedMyeloablative AgonistsPrecursor Cell Lymphoblastic Leukemia-LymphomaPrognosisRecurrenceRetrospective StudiesRisk FactorsSiblingsTransplantation ConditioningMyeloablative Agonists

Identifiers

PMID27686376
PMCPMC5210244
OpenAlexW2525939690

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.